|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.268 SEK | +2.42% |
|
+0.32% | -35.63% |
| 06-08 | Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue | FW |
| 06-05 | IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026 | CI |
Projected Income Statement: IRLAB Therapeutics AB
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 102 | 141.8 |
| Change | - | - | -70.58% | -90.71% | 1,566.57% | -39.28% | 77.51% | 39.02% |
| EBITDA 1 | - | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -27.6 | 37.3 |
| Change | - | - | -293.28% | -62.88% | 60.03% | -26.3% | 69.02% | 235.14% |
| EBIT 1 | - | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.6 | 33.3 |
| Change | - | - | -315.14% | -59.81% | 58.45% | -24.35% | 66.17% | 205.38% |
| Interest Paid 1 | - | -0.796 | -0.297 | 2.927 | -8.018 | -16.61 | - | - |
| Earnings before Tax (EBT) 1 | - | 51.78 | -113.4 | -177.8 | -83.13 | -110 | - | - |
| Change | - | - | -319.01% | -56.82% | 53.26% | -32.34% | - | - |
| Net income 1 | -91.65 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -32.6 | 33.3 |
| Change | - | 156.5% | -319.01% | -56.82% | 53.26% | -32.34% | 70.37% | 202.15% |
| Announcement Date | 15/04/21 | 23/02/22 | 23/02/23 | 07/02/24 | 12/02/25 | 25/02/26 | - | - |
1SEK in Million
Estimates
Forecast Balance Sheet: IRLAB Therapeutics AB
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | -402 | -253 | -111 | -63.4 | - | - | - |
| Change | - | - | 37.06% | 56.13% | 42.88% | - | - | - |
| Announcement Date | 15/04/21 | 23/02/22 | 23/02/23 | 07/02/24 | 12/02/25 | 25/02/26 | - | - |
Estimates
Cash Flow Forecast: IRLAB Therapeutics AB
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 0.137 | 0.394 | 0.708 | 2.876 | 0.293 | 0.199 |
| Change | - | 187.59% | 79.7% | 306.21% | -89.81% | -32.08% |
| Free Cash Flow (FCF) 1 | -51.69 | -55.24 | 69.69 | -103.6 | -99.98 | -38.77 |
| Change | - | -6.86% | 226.16% | -248.61% | 3.46% | 61.23% |
| Announcement Date | 07/04/20 | 15/04/21 | 08/04/22 | 29/04/24 | 29/04/24 | 25/04/25 |
1SEK in Million
Estimates
Forecast Financial Ratios: IRLAB Therapeutics AB
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
| EBITDA Margin (%) | - | - | 26.98% | -177.2% | -3,107.59% | -74.53% | -155.02% | -27.06% | 26.3% |
| EBIT Margin (%) | - | - | 25.3% | -185.01% | -3,183.6% | -79.38% | -162.54% | -30.98% | 23.48% |
| EBT Margin (%) | - | - | 24.92% | -185.5% | -3,132.07% | -87.85% | -191.45% | - | - |
| Net margin (%) | - | - | 24.92% | -185.5% | -3,132.07% | -87.85% | -191.45% | -31.96% | 23.48% |
| FCF margin (%) | - | - | - | - | -2,908.65% | -69.52% | - | - | - |
| FCF / Net Income (%) | - | - | - | - | 92.87% | 79.14% | - | - | - |
Profitability | |||||||||
| ROA | -27.48% | -19.77% | 7.8% | -17.59% | -44.96% | -29.11% | - | - | - |
| ROE | -48.75% | -34.61% | 13.86% | -32.86% | -87.48% | -112.03% | - | - | - |
Financial Health | |||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - | - |
Capital Intensity | |||||||||
| CAPEX / Current Assets (%) | - | - | 0.34% | 4.7% | 5.16% | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | 1.26% | -2.65% | -0.17% | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | -0.18% | - | - | - | - |
Items per share | |||||||||
| Cash flow per share 1 | 2.564 | 5.353 | 7.766 | 4.873 | 2.146 | 1.29 | - | - | - |
| Change | - | 108.79% | 45.08% | -37.25% | -55.97% | -39.88% | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | 4.218 | 6.723 | 7.72 | 5.607 | 2.232 | 0.6292 | - | - | - |
| Change | - | 59.39% | 14.83% | -27.37% | -60.2% | -71.81% | - | - | - |
| EPS 1 | -2.368 | -1.922 | 1 | -2.188 | -3.429 | -1.603 | - | - | - |
| Change | - | 18.82% | 152.02% | -318.8% | -56.71% | 53.26% | - | - | - |
| Nbr of stocks (in thousands) | 43,110 | 51,748 | 51,748 | 51,868 | 51,868 | 51,868 | - | - | - |
| Announcement Date | 07/04/20 | 15/04/21 | 08/04/22 | 29/04/24 | 29/04/24 | 25/04/25 | - | - | - |
1SEK
Estimates
| 2025 | 2026 * | |
|---|---|---|
| P/E Ratio | - | - |
| PBR | - | - |
| EV / Sales | 2.91x | 1.03x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
